{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-25-000040","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.491840+00:00","generated_at":"2026-05-19T06:37:27.042017+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gossamer Bio completes enrollment in Phase 3 PROSERA study for seralutinib in PAH (n=390)","bullets":["Global registrational Phase 3 PROSERA study fully enrolled; topline results expected February 2026.","Enrolled 390 patients vs 86 in Phase 2; mean 6MWD 374 m (vs 408 m), NT-proBNP 987 ng/L (vs 628).","74% of patients are Functional Class III vs 42% in Phase 2; enrichment criteria applied to target responders.","Study is double-blind, placebo-controlled, primary endpoint change in 6MWD at week 24.","Seralutinib developed with Chiesi Group; positive milestone for first-in-class PAH treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-25-000040","json":"https://secwatch.observer/filing/0001728117-25-000040.json","markdown":"https://secwatch.observer/filing/0001728117-25-000040.md","text":"https://secwatch.observer/filing/0001728117-25-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000040/0001728117-25-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000040/goss-20250616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:37:27.042017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}